Pull to refresh
Logo
FDA clears personalized magnetic brain therapy for PTSD after trial reports high remission

FDA clears personalized magnetic brain therapy for PTSD after trial reports high remission

New Capabilities

Wave Neuroscience reported 68% remission and 52% symptom reduction in a trial whose full results remain unpublished.

3 days ago: Trial results announced

Overview

Updated 2 hours ago

The Food and Drug Administration cleared a personalized magnetic brain therapy for PTSD in June 2026. The maker's trial reports a 68% remission rate, more than four times the maximum seen in a 2020 review of standard PTSD medications.

That figure comes from Wave Neuroscience, the California company behind the device. The full results — sample size, symptom scale, and how remission was defined — have not been published. If peer review confirms them, millions of PTSD patients gain a documented non-drug option. If not, the 68% is just a press release.

Why it matters

If the 68% remission rate survives peer review, millions of PTSD patients gain a non-drug option that has outperformed standard medication.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

68%
Reported PTSD remission rate
Company-reported figure from the MeRT trial; not yet published or peer-reviewed.
52%
Reported PTSD symptom reduction
Measured over a five-to-six-week course of daily sessions.
10.9%
Maximum remission in 2020 medication review
Comparison benchmark cited in the announcement; the two studies used different methods.
6%
US lifetime PTSD prevalence
About 6% of Americans experience PTSD at some point in their lives.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

2024 October 2026

3 events Latest: 3 days ago
  1. Trial results announced

    Latest Statement

    Texas A&M releases trial figures: 52% symptom reduction and 68% remission over a five-to-six-week course, with results not yet published.

  2. FDA clears MeRT for PTSD

    Regulatory

    FDA clears the magnetic stimulation system for PTSD; the company announces the decision June 10 and trade press reports it June 12.

  3. FDA grants MeRT breakthrough designation

    Regulatory

    MeRT receives FDA Breakthrough Device designation, speeding its path to clearance.

Scenarios

1

Peer review confirms a remission rate near 68%

Possible Resolves by Q2 2027

Discussed by: Wave Neuroscience's own announcement via Texas A&M

Wave publishes full results from its double-blind, randomized, multisite trial in a medical journal. If the sample is meaningful and the remission figure lands between 50% and 68%, MeRT becomes a documented non-drug PTSD option with results several times better than medication alone.

2

Published data reveal a weaker effect than announced

Uncertain Resolves by Q2 2027

Discussed by: Morning Overview's independent review of the release

The announcement did not say how many people took part, which scale measured symptoms, how remission was defined, or how long follow-up lasted. If the published data show a smaller, less durable effect, the 68% figure shrinks and the comparison to medication loses force.

3

Clearance holds, but adoption hinges on payer coverage

Likely Resolves by End of 2027

Discussed by: Trade and clinical press coverage

FDA clearance does not guarantee clinics offer the treatment or insurers pay for it. A five-to-six-week course of daily sessions is costly, so coverage decisions by insurers and Medicare will determine how many patients can actually access MeRT.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

2021-2026

MDMA-assisted therapy for PTSD (2021-2026)

A living meta-analysis of six randomized trials covering 286 participants found MDMA-assisted therapy roughly doubled remission odds versus controls. Reported remission reached 68% at one year of follow-up in some cohorts.

Then

The FDA granted expanded access, letting treatment-resistant patients receive the therapy before full approval.

Now

MDMA remains a Schedule 1 drug, and the therapy still lacks final FDA approval.

Why this matters now

It is the other leading non-drug PTSD treatment with remission rates near 68%, showing both the promise and the regulatory friction such therapies face.

2008

Transcranial magnetic stimulation for depression (2008)

The FDA first cleared repetitive transcranial magnetic stimulation (rTMS) for major depression, giving psychiatrists a non-drug, non-invasive option for patients who had not responded to medication.

Then

rTMS became a covered therapy and is now standard for treatment-resistant depression.

Now

Its adoption took years and depended on payer coverage and repeated sessions, a pattern likely to repeat for MeRT.

Why this matters now

MeRT uses the same technology family — magnetic pulses through the scalp — applied to PTSD with EEG-guided personalization.

Sources

(6)